Upon tumor progression, the patients were re‐transferred with >95% pure mutation‐specific Th1 cells, which effectively suppressed the tumor volume,351 indicating that CD4+ T cells can also be harnessed for ACT treatment. The gene discussed is CD4; the disease is neoplasm.